evidence table

Coenzyme Q10 Supplementation Energy Randomized Trial Evidence Table

Structured evidence table for Coenzyme Q10 Supplementation Energy Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Coenzyme Q10 Supplementation Energy Randomized TrialDespite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Supplementation Energy Randomized TrialAdditionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Supplementation Energy Randomized TrialBanach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence.3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Supplementation Energy Randomized TrialRoth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year ().3Wu Xun (2026)Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
Coenzyme Q10 Supplementation Energy Randomized TrialMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30% [...].4Rodriguez-Ramiro I (2026)Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside.
topicCoenzyme Q10 Supplementation Energy Randomized Trial
claimDespite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Supplementation Energy Randomized Trial
claimAdditionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Supplementation Energy Randomized Trial
claimBanach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence.
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Supplementation Energy Randomized Trial
claimRoth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year ().
evidence level3
citationWu Xun (2026)
sourceAdvances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
topicCoenzyme Q10 Supplementation Energy Randomized Trial
claimMetabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30% [...].
evidence level4
citationRodriguez-Ramiro I (2026)
sourceAdvances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside.

Learn next

Related evidence and supplement guides

SupplementCoenzyme Q10 (CoQ10)A coenzyme essential for mitochondrial ATP energy production, supporting heart health and cellul...SupplementCoQ10 (Ubiquinol)Mitochondrial cofactor that declines with age and statin use — supports cardiac energy, fertilit...GuideCoenzyme Q10 Energy Randomized Trial: What the Evidence SaysCoenzyme Q10 Energy Randomized Trial has 2 source documents in the current Migaku evidence datab...GuideCoenzyme Q10 Cholesterol Randomized Trial: What the Evidence SaysCoenzyme Q10 Cholesterol Randomized Trial has 2 source documents in the current Migaku evidence...GuideCoenzyme Q10 Skin Aging Randomized Trial: What the Evidence SaysCoenzyme Q10 Skin Aging Randomized Trial has 2 source documents in the current Migaku evidence d...GuideCoenzyme Q10 Energy Meta-analysis: What the Evidence SaysCoenzyme Q10 Energy Meta-analysis has 2 source documents in the current Migaku evidence database...CompareCoenzyme Q10 (Ubiquinone) vs UbiquinolUbiquinone is the traditional, oxidized form of CoQ10. Ubiquinol is the fully reduced, active an...CompareCoQ10 vs PQQCoQ10 acts as the internal spark plug that helps mitochondria convert oxygen and food into ATP e...

Source documents

  1. Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives
  2. Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside.